Leukemia Hodgkin Articles & Analysis
4 news found
These strategic additions to the leadership team are timed with the near completion of the safety portion of a pivotal clinical trial in treating “no-option” Non-Hodgkin’s Lymphoma/Leukemia patients. The safety dose-escalation portion of the study is projected to be completed in Q1-Q2 2022 with the efficacy portion, already approved by FDA, set ...
Sharman pioneered the use of B-cell receptor antagonists and has since led numerous studies contributing to the development and regulatory approval of BTK and PI3K inhibitors in chronic lymphocytic leukemia and Non-Hodgkin’s lymphoma. Beyond these therapeutic classes, Dr. ...
AVM Biotechnology, a clinical-stage company, announced today FDA permission to modify its ongoing clinical study, AVM0703-001, entitled “The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma”. The initial protocol, a 3 x 3-based design, called for dose escalation of 3 mg/kg for each of the six cohorts, ranging from 6 mg/kg to 21 mg/kg, with a minimum of three ...
It also provides researchers the ability to profile 40 DNA targets and 29 fusion driver genes, enabling detection of more than 600 fusion isotypes to identify biomarkers associated with myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Traditionally, analyzing myeloid samples involves serial single-gene testing to determine ...